Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs placebo: Total number of new lesions over 2-month treatment period
- Population
- Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination; excluding those with Behcet's disease, Reiter's syndrome, recurrent erythema multiforme, viral infection, coeliac disease, Crohn's disease, ulcerative colitis, anaemia or haematinic deficiency
- Intervention
- Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months)
- Comparison
- placebo
- Outcome
- Total number of new lesions over 2-month treatment period
Prednisone (oral, commencing 25 mg with phased dose reduction over 2… led to lower total number of new lesions over 2-month treatment period compared with placebo; GRADE not reported.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Placebo Total number of new lesions over 2-month treatment period · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and… · 2 months Prednisone (oral, commencing 25 mg with phased dose reduction over 2… led to lower total number of new lesions over 2-month treatment period compared with placebo; GRADE not reported. Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) (2012) · Cochrane All outcomes | MD -4.20 [-4.84, -3.56] | 1 study · 40 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes | 2012-06 | Not listed | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Montelukast (leukotriene receptor antagonist) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS),… · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.